NEW YORK — In a video perspective from OSN New York 2015, Kendall E. Donaldson, MD, MS, discusses the latest studies comparing femtosecond laser safety and refractive outcomes with traditional phacoemulsification in cataract surgery.
Uncategorized
Uncategorized
TearScience® Announces New Pricing Strategy For Core LipiFlow® Technology Used For Treatment Of Dry Eye From Meibomian Gland Disease (MGD)
MORRISVILLE, N.C.–(BUSINESS WIRE)–TearScience, a privately held medical device company, has announced a 50% price cut, effective immediately, on the single-use activators used with the LipiFlow treatment platform for Meibomian Gland Disease (MGD). The move is just one component of an overall strategy to make the LipiFlow and LipiView® Technologies more accessible to Eye Care Professionals (ECPs), who can then, in turn, use them to evaluate and intervene earlier in MGD for the benefit of the m
Uncategorized
Visually Impaired Worker Applauded for Enthusiasm and Perseverance
WILMINGTON, Del.–(BUSINESS WIRE)–Often referred to as “Mighty Mouse” for her enthusiasm and perseverance, Delaware Park’s senior environmental worker Linda Rieker, recently received the Community Employment Placement of the Year award from the Delaware Division for the Visually Impaired (DVI). The first Celebrations of Champions event, held at Dover Downs Hotel & Casino, also honored White Cane Day, World Blindness Awareness Month and National Disability Employment Awareness Month. Known
Dry eye disease: OPUS-3 phase 3 trial with lifitegrast meets primary and key secondary endpoints
Shire plc has announced positive topline results from OPUS-3, a phase 3 efficacy and safety study of lifitegrast versus placebo.
Uncategorized
Sustained release OTX-TP reduces IOP in phase 2b clinical trial
Ocular Therapeutix announced that sustained release OTX-TP achieved “clinically meaningful” reduction in IOP in its phase 2b study, according to a press release reporting topline results.OTX-TP (sustained release travoprost) is intended for treatment of glaucoma and ocular hypertension.
Cynosure obtains medical device license from Health Canada to market MonaLisa Touch for treatment of GSM symptoms
Cynosure, Inc. today announced that it has received a medical device license issued by Health Canada to market MonaLisa Touch® for the treatment of symptoms related to Genitourinary Syndrome of Menopause (GSM), including vaginal dryness, vaginal burning, vaginal itching, pain, dysuria and dyspareunia.